SHOULD SULFONYLUREAS REMAIN THE DRUGS OF FIRST CHOICE IN ADDITION TO METFORMIN?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article reviews the results of the largest multi-center study evaluated the efficacy and safety of sulfonylurea (SU) drugs. The data from meta-analysis showed a high efficacy of SU among all oral hypoglycemic drugs. Along with efficiency, according to a number of clinical studies SU preparations have high cardiac safety. Despite the increased likelihood of hypoglycemic events, in routine clinical practice, the use of drugs with the SU is not associated with very high risk of hypoglycemic reactions. The risk can be minimized by pre-determination of the individual glycemic targets and the recommendations of the fractional diet and dosed physical activity. The listed lets SU-preparations to be considered as effective and fairly safe drugs, that remain relevant today.

Full Text

Restricted Access

About the authors

Tatiana Yulievna Demidova

Russian Medical Academy of Postgraduate Education

Email: t.y.demidova@gmail.com
MD, Professor; Professor of the Department of Endocrinology and Diabetology 125315, Moscow, 20 Chasovaya St

Svetlana Yevgenievna Isaeva

Russian Medical Academy of Postgraduate Education

intern, Department of Endocrinology and Diabetology 125315, Moscow, 20 Chasovaya St

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
  2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 1993;329(14):977-86.
  3. Hirst J.A., Farmer A.J., Dyar A., Lung T.W.C., Stevens R.J. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56:973-84.
  4. Al-Ozairi E., Sibal L., Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas? Diabetes Care. 2007;30:1677-80.
  5. Heine R.J. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: part II - ‘the cons'. Horm. Metab. Res. 1996;28:522-6.
  6. Tremble J.M., Donaldson D. Is continued weight gain inevitable in type 2 diabetes mellitus? J. R. Soc. Promot. Health. 1999;119:235-9.
  7. Scholz G., Schneider K., Knirsch W., Becker G. Efficacy and tolerability of glimepiride in daily practice: a noninterventional observational cohort study. Clin. Drug Invest. 2001 ;21 (9):597-604.
  8. Nauck M., Frid A., Hermansen K., Thomsen A.B., During M., Shah N., Tankova T., Mitha I., Matthews D.R. Longterm efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 2013;15:204-12.
  9. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm. Metab. Res. 1996;28(9):434-9.
  10. Draeger K.E., Wernicke-Panten K., Lomp H.J., Schüler E., Rosskamp R. Long-term treatment of type 2 Diabetic Patients with New Oral Antidiabetic Agent Glimepiride (Amaryl): a double blind comparision with Glibenclamide. Horm. Metab. Res. 1996;28:419-25.
  11. Paes A.H., Bakker A., Soe-Agnie C.J. Impact of doses frequency on patient compliance. Diabet Care. 1997;20(10):1512-7.
  12. Eckel J. Direct effects of glimepinde on protein expression of cardiac glucose transporters. Horm. Metab. Res. 1996;28:508-11.
  13. Umpierrez G., Issa M., Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 2006;22(4):751-9.
  14. Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., Dugi K.A., Woerle H.J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, doubleblind, non-inferiority trial. Lancet. 2012;380:475-83.
  15. Schernthaner G., Grimaldi A., Di-Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004;34:535-42.
  16. Rahman I.U., Malik S.A., Bashir M., Khan R.U., Idrees M. Monotherapy with metformin or glimepiride and changes in serum sialic acid in type 2 diabetes mellitus. Brit. J. Diab. Vas. Dis. 2011 ;11 (3) :137-40.
  17. Garber A.J. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch. Intern. Med. 2003; 163(15):1781 -2.
  18. Riddle M.C. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm. Metab. Res. 1996;28:430-3.
  19. Riddle M.C., Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998;21 (7):1052-7.
  20. Fritsche A., Schweitzer M.A., Haring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 2003;138(12):952-9.
  21. Mocanu M.M., Maddock H.L., Baxter G.F., Lawrence C.L., Standen N.B., Yellon D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001 ;103(25) :3111-6.
  22. Campbell R.K. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 1998;32(10):1044-52.
  23. Geisen K., Vegh A., Krause E., Papp J.G. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm. Metab. Res. 1996;28:496-507.
  24. Goldberg R.B., Holvey S.M., Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol 201 Study Group. Diabetes Care. 1996;19(8):849-56.
  25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
  26. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., Viberti G.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427-43.
  27. Martin S., Kolb H., Beuth J., van Leendert R., Schneider B., Scherbaum W.A. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia. 2003;46(12):1611-7.
  28. Draeger K., Wernicke-Panten K., Lomp H.J., Schuler E., Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm. Metab. Res. 1996;28:419-25.
  29. Muller G., Hartz D., Punter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim. Biophys. Acta. 1994;1191:267-77.
  30. Muller G., Satoh Y., Geisen K. Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res. Clin. Pract. 1995;28 Suppl:S115-S137.
  31. Schauer P.R., Kashyap S.R., Wolski K., Brethauer S.A., Kirwan J.P., Pothier C.E., Thomas S., Abood B., Nissen S.E., Bhatt D.L. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 2012;366:1567-76.
  32. Hoechst-Roussel Pharmaceuticals, Inc Amaryl (glimepiride) prescribing information. Somerville, NJ; Hoechst-Roussel Pharmaceuticals, Inc; 1995.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies